MoonLake Investors Press Securities Class Action Over Sonelokimab Claims

Overview

• A class action has been filed on behalf of purchasers of MoonLake Immunotherapeutics common stock from March 10, 2024 through September 29, 2025.
• Notices allege MoonLake misled investors by promoting sonelokimab as superior to monoclonal therapies without proven advantages, with analysts later calling the Phase 3 results disastrous.
• Rosen Law’s summary says the complaint centers on SLK and BIMZELX targeting IL-17A and IL-17F and asserts SLK’s Nanobody design did not deliver a superior clinical benefit or efficacy.
• The suits assert violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
• Law firms including Bernstein Liebhard, DJS Law Group, and Rosen are soliciting shareholders, and no class has been certified to date.